Logo image of GUTS

FRACTYL HEALTH INC (GUTS) Stock Fundamental Analysis

NASDAQ:GUTS - Nasdaq - US35168W1036 - Common Stock - Currency: USD

1.51  -0.1 (-6.21%)

After market: 1.5107 +0 (+0.05%)

Fundamental Rating

2

Taking everything into account, GUTS scores 2 out of 10 in our fundamental rating. GUTS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. GUTS may be in some trouble as it scores bad on both profitability and health. GUTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GUTS had negative earnings in the past year.
GUTS had a negative operating cash flow in the past year.
GUTS had negative earnings in each of the past 5 years.
In the past 5 years GUTS always reported negative operating cash flow.
GUTS Yearly Net Income VS EBIT VS OCF VS FCFGUTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

GUTS has a Return On Assets of -54.34%. This is in the lower half of the industry: GUTS underperforms 68.95% of its industry peers.
GUTS's Return On Equity of -137.06% is on the low side compared to the rest of the industry. GUTS is outperformed by 70.00% of its industry peers.
Industry RankSector Rank
ROA -54.34%
ROE -137.06%
ROIC N/A
ROA(3y)-93.33%
ROA(5y)-165.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GUTS Yearly ROA, ROE, ROICGUTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

GUTS's Gross Margin of 46.39% is on the low side compared to the rest of the industry. GUTS is outperformed by 60.00% of its industry peers.
GUTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GUTS Yearly Profit, Operating, Gross MarginsGUTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

GUTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
GUTS has more shares outstanding than it did 1 year ago.
GUTS has a worse debt/assets ratio than last year.
GUTS Yearly Shares OutstandingGUTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
GUTS Yearly Total Debt VS Total AssetsGUTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

GUTS has an Altman-Z score of -5.13. This is a bad value and indicates that GUTS is not financially healthy and even has some risk of bankruptcy.
GUTS's Altman-Z score of -5.13 is on the low side compared to the rest of the industry. GUTS is outperformed by 70.53% of its industry peers.
GUTS has a Debt/Equity ratio of 0.60. This is a neutral value indicating GUTS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, GUTS is not doing good in the industry: 66.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -5.13
ROIC/WACCN/A
WACC7.46%
GUTS Yearly LT Debt VS Equity VS FCFGUTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.58 indicates that GUTS has no problem at all paying its short term obligations.
GUTS's Current ratio of 5.58 is amongst the best of the industry. GUTS outperforms 80.53% of its industry peers.
A Quick Ratio of 5.57 indicates that GUTS has no problem at all paying its short term obligations.
GUTS's Quick ratio of 5.57 is amongst the best of the industry. GUTS outperforms 85.26% of its industry peers.
Industry RankSector Rank
Current Ratio 5.58
Quick Ratio 5.57
GUTS Yearly Current Assets VS Current LiabilitesGUTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

GUTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.94%.
EPS 1Y (TTM)-46.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.22%

3.2 Future

GUTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.04% yearly.
GUTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 379.20% yearly.
EPS Next Y95.71%
EPS Next 2Y38.76%
EPS Next 3Y24.04%
EPS Next 5YN/A
Revenue Next Year-55.75%
Revenue Next 2Y-41.42%
Revenue Next 3Y379.2%
Revenue Next 5YN/A

3.3 Evolution

GUTS Yearly Revenue VS EstimatesGUTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
GUTS Yearly EPS VS EstimatesGUTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GUTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GUTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GUTS Price Earnings VS Forward Price EarningsGUTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GUTS Per share dataGUTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as GUTS's earnings are expected to grow with 24.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.76%
EPS Next 3Y24.04%

More info and screens

0

5. Dividend

5.1 Amount

GUTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FRACTYL HEALTH INC

NASDAQ:GUTS (2/7/2025, 8:00:01 PM)

After market: 1.5107 +0 (+0.05%)

1.51

-0.1 (-6.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners84.01%
Inst Owner Change-0.01%
Ins Owners3.75%
Ins Owner Change2.39%
Market Cap72.63M
Analysts85
Price Target15.81 (947.02%)
Short Float %5.96%
Short Ratio7.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.58%
Min EPS beat(2)5.88%
Max EPS beat(2)23.27%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)233.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 748.77
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.34%
ROE -137.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.39%
FCFM N/A
ROA(3y)-93.33%
ROA(5y)-165.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 339.02%
Cap/Sales 1719.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.58
Quick Ratio 5.57
Altman-Z -5.13
F-Score6
WACC7.46%
ROIC/WACCN/A
Cap/Depr(3y)48.49%
Cap/Depr(5y)31.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.01%
EPS Next Y95.71%
EPS Next 2Y38.76%
EPS Next 3Y24.04%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.22%
Revenue Next Year-55.75%
Revenue Next 2Y-41.42%
Revenue Next 3Y379.2%
Revenue Next 5YN/A
EBIT growth 1Y-2.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.97%
EBIT Next 3Y-55.72%
EBIT Next 5YN/A
FCF growth 1Y-39.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.47%
OCF growth 3YN/A
OCF growth 5YN/A